Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Australian Clinical LabsASX:ACL +0.71%73 ROA % is 6.28% as of Jun. 2026, which is 9% above its 10-year median of 5.75. GuruFocus rates ASX:ACL with a GF Score™ of 73/100 and a GF Value™ of A$2.95 (Fairly Valued). The stock has 8 warning signs investors should review. Among 212 Medical Diagnostics & Research companies, Australian Clinical Labs ranks better than 71.23% on this metric.
ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. Australian Clinical Labs's annualizedNet Income for the quarter that ended in Jun. 2026 was A$36.3 Mil.
Australian Clinical Labs's average Total Assets over the quarter that ended in Jun. 2026 was A$577.6 Mil. Therefore, Australian Clinical Labs's annualized ROA % for the quarter that ended in Jun. 2026 was 6.28%.
The historical rank and industry rank for Australian Clinical Labs's ROA % or its related term are showing as below:
ASX:ACL'
s ROA % Range Over the Past 10 Years
Min: 4.06 Med: 5.75 Max: 32.33
Current: 4.11
During the past 6 years, Australian Clinical Labs's highest ROA % was 32.33%. The lowest was 4.06%. And the median was 5.75%.
ASX:ACL's ROA % is ranked better than 71.23% of 212
companies
in the Medical Diagnostics & Research industry
Industry Median: -0.605
vs ASX:ACL: 4.11
Australian Clinical Labs (ASX:ACL) ROA % Explanation
ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A banks ROA % is typically well under 2%.
Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:
Note:
The Net Income data used here is two times the semi-annual (Jun. 2026) net income data. The Revenue data used here is two times the semi-annual (Jun. 2026) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.
E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Australian Clinical Labs's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Australian Clinical Labs ROA % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Australian Clinical Labs's ROA % distribution charts can be found below:
* The bar in red indicates where Australian Clinical Labs's ROA % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is two times the semi-annual (Jun. 2026) net income data.
ROA % is displayed in the 30-year financial page.
Australian Clinical Labs (ASX:ACL) has a ROA % of 6.28% as of Jun. 2026. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Australian Clinical Labs and its competitors. This is near median its historical median of 5.75. Over the past decade, Australian Clinical Labs' ROA % has ranged from 4.06 to 32.33. According to the industry distribution chart, Australian Clinical Labs ranks #61 out of 212 companies in the Medical Diagnostics & Research industry, placing it in the top 28.8%.
Is Australian Clinical Labs' ROA % too high?
Australian Clinical Labs' current ROA % of 6.28% is near median its 10-year median of 5.75. Over the past 10 years, this metric has ranged from a low of 4.06 to a high of 32.33. Based on the distribution chart, Australian Clinical Labs ranks #61 out of 212 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Australian Clinical Labs has a GF Score™ of 73/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Australian Clinical Labs' ROA % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Australian Clinical Labs ranks #61 out of 212 companies for ROA %. This puts Australian Clinical Labs in the upper half of its industry. Historically, Australian Clinical Labs' own ROA % has ranged from 4.06 to 32.33 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROA % for a Medical Diagnostics & Research company?
A good ROA % depends on the Medical Diagnostics & Research industry context. However, ROA % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROA % mean?
A high ROA % can signal that a stock is expensive relative to its fundamentals. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Australian Clinical Labs and its competitors. Australian Clinical Labs's current ROA % is 6.28%, which is near median its own 10-year median of 5.75. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Australian Clinical Labs stock overvalued right now?
Based on GuruFocus' analysis, Australian Clinical Labs (ASX:ACL) is currently considered Fairly Valued. The stock's GF Value™ is A$2.95, compared to a current price of A$2.84 — trading 3.7% below its estimated fair value. The current ROA % is 6.28%, which is near median its 10-year median of 5.75. Australian Clinical Labs' overall GF Score™ is 73/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROA % calculated?
ROA % is calculated from a company's financial statements. For Australian Clinical Labs (ASX:ACL), the current ROA % is 6.28% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Australian Clinical Labs (ASX:ACL) Overvalued in 2026?
Based on GuruFocus' analysis, Australian Clinical Labs stock appears to be undervalued.
The current stock price of A$2.84 is trading 3.7% below its estimated GF Value™ of A$2.95.
GuruFocus considers Australian Clinical Labs to be Fairly Valued.
Key valuation signals for ASX:ACL:
ROA %: 6.28% (near median its 10-year median of 5.75)
GF Value™: A$2.95 vs. price of A$2.84 (3.7% below fair value)
No single metric tells the full story. See the ASX:ACL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Australian Clinical Labs is Australia's third-largest private pathology provider. ACL earns almost its entire group revenue from pathology services in Australia, which are mostly earned via the publicly funded health Medicare system. ACL is well established in the states of Western Australia, South Australia, Victoria, and the Northern Territory.
73GF Score
Get the complete analysis for ASX:ACL
ROA % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:ACL has been successfully added to your 
